These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20647630)

  • 1. We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
    Matsuda N
    Circ J; 2010 Aug; 74(8):1526-7. PubMed ID: 20647630
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
    Wai B; Kearney LG; Hare DL; Ord M; Burrell LM; Srivastava PM
    Cardiovasc Diabetol; 2012 Feb; 11():14. PubMed ID: 22330091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is carvedilol better than other beta-blockers for heart failure?
    Rain C; Rada G
    Medwave; 2015 Jun; 15 Suppl 1():e6168. PubMed ID: 26135382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
    de Boer RA; van Veldhuisen DJ
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):261-3. PubMed ID: 18418705
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers for heart failure: why you should use them more.
    Ong HT; Kow FP
    J Fam Pract; 2011 Aug; 60(8):472-7. PubMed ID: 21814642
    [No Abstract]   [Full Text] [Related]  

  • 7. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
    Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
    Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot.
    Soma K; Yao A; Saito A; Inaba T; Ishikawa Y; Hirata Y; Komuro I
    Int Heart J; 2018 Sep; 59(5):1169-1173. PubMed ID: 30101848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
    Wali RK; Iyengar M; Beck GJ; Chartyan DM; Chonchol M; Lukas MA; Cooper C; Himmelfarb J; Weir MR; Berl T; Henrich WL; Cheung AK
    Circ Heart Fail; 2011 Jan; 4(1):18-26. PubMed ID: 21036889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure.
    Fragasso G; Salerno A; Margonato A
    Am J Cardiol; 2008 Aug; 102(4):506-7. PubMed ID: 18678315
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of short-term carvedilol on the cardiac sympathetic activity assessed by 123I-MIBG scintigraphy.
    Miranda SM; Mesquita ET; Dohmann HF; Azevedo JC; Barbirato GB; Freire Fde L; Ribeiro ML; Nóbrega AC; Coimbra A; Mesquita CT
    Arq Bras Cardiol; 2010 Mar; 94(3):308-12, 328-32. PubMed ID: 20730258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
    Albert NM
    Crit Care Nurse; 2007 Dec; 27(6):62-72. PubMed ID: 18032686
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
    J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
    Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
    Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvedilol improves uptake-1 in patients with systolic congestive heart failure.
    Machida M; Takechi S; Fujimoto T; Kakinoki S; Nomura A
    J Cardiovasc Pharmacol; 2012 Feb; 59(2):175-81. PubMed ID: 21997260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
    Susa T; Kobayashi S; Tanaka T; Murakami W; Akashi S; Kunitsugu I; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Ueyama T; Okamura T; Yano M; Matsuzaki M
    Circ J; 2012; 76(1):117-26. PubMed ID: 22008315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
    Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
    Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
    Ramaswamy K
    Card Electrophysiol Rev; 2003 Sep; 7(3):229-32. PubMed ID: 14739719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol in class IV heart failure.
    Hoffman I
    J Am Coll Cardiol; 1999 Dec; 34(7):2149-50. PubMed ID: 10588239
    [No Abstract]   [Full Text] [Related]  

  • 20. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.